Why the study?
Postoperative ileus and impaired gastrointestinal functions remain a significant issue after colorectal resection despite enhanced recovery programmes, with little evidence distinguishing treatments assessed within versus outside these programmes.
Do treatments like chewing-gum or Alvimopan reduce postoperative ileus and improve GI function recovery in patients undergoing colorectal surgery within an enhanced recovery programme?
Do treatments like chewing-gum or Alvimopan reduce postoperative ileus and improve GI function recovery in patients undergoing colorectal surgery within an enhanced recovery programme?
Chewing gum is not effective for GI function recovery in ERP after colorectal surgery, while Alvimopan shows potential but requires further randomized controlled trials.
Evidence on POI treatments within ERP remains limited; leaves open optimal GI recovery strategies after colorectal resection.
Despite a significant improvement with enhanced recovery programmes (ERP), gastro-intestinal (GI) functions that are impaired after colorectal resection and postoperative ileus (POI) remain a significant issue. In the literature, there is little evidence of the distinction between the treatment assessed within or outside ERP. The purpose was to evaluate the efficiency of treatments to reduce POI and improve GI function recovery within ERP. A search was performed in PubMed and Scopus on 20 September 2019. The studies were included if they compared the effect of the administration of a treatment aiming to treat or prevent POI or improve the early functional outcomes of colorectal surgery within an ERP. The main outcome measures were the occurrence of postoperative ileus, time to first flatus and time to first bowel movement. Treatments that were assessed at least three times were included in a meta-analysis. Among the analysed studies, 28 met the eligibility criteria. Six of them focused on chewing-gum and were only randomized controlled trials (RCT) and 8 of them focused on Alvimopan but none of them were RCT. The other measures were assessed in less than 3 studies over RCTs (n = 11) or retrospective studies (n = 2). In the meta-analysis, chewing gum had no significant effect on the endpoints and Alvimopan allowed a significant reduction of the occurrence of POI. Chewing-gum was not effective on GI function recovery in ERP but Alvimopan and the other measures were not sufficiently studies to draw conclusion. Randomised controlled trials are needed.Systematic review registration number CRD42020167339.
No takes yet. Share an insight, caveat, or question.
Hamel et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: